RxDoctor Payments Data

Timothy le

Physician Assistant · Las Vegas, NVNPI 1396409694

Payments from drug & device makers

$3,827in general payments, 2019–2025

Across 163 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Forte Bio-pharma LLC$669
  • AbbVie$591
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$554
  • AstraZeneca$521
  • Bayer$202
  • Novo Nordisk$184
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,820100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,827 in reported general payments places this provider in the 85th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$14,434
Medicare patients
90
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide54$64,218
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen621$36,774
RelistorMethylnaltrexone Bromide11$26,476
JardianceEmpagliflozin15$15,774
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen453$13,676
Xtampza ErOxycodone Myristate22$10,078
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,589
MovantikNaloxegol Oxalate15$8,050
Diclofenac Sodium91$6,812
Lidocaine58$6,697
OxycontinOxycodone Hcl16$5,877
Morphine Sulfate ErMorphine Sulfate170$4,010
Methocarbamol40$3,879
Oxycodone Hcl201$3,288
Varenicline Tartrate12$3,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$79$64,21854 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$554$26,47611 claims
Collegium Pharmaceutical, Inc.Xtampza Er$75$10,07822 claims
AstraZenecaBreztri Aerosphere$521$9,58916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →